305 related articles for article (PubMed ID: 27863474)
1. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
Orue A; Chavez V; Strasberg-Rieber M; Rieber M
BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
[TBL] [Abstract][Full Text] [Related]
2. 3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants.
Konstantakou EG; Voutsinas GE; Velentzas AD; Basogianni AS; Paronis E; Balafas E; Kostomitsopoulos N; Syrigos KN; Anastasiadou E; Stravopodis DJ
Mol Cancer; 2015 Jul; 14():135. PubMed ID: 26198749
[TBL] [Abstract][Full Text] [Related]
3. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells.
Rieber M; Strasberg-Rieber M
Biochem Pharmacol; 2012 Dec; 84(12):1563-70. PubMed ID: 22982566
[TBL] [Abstract][Full Text] [Related]
5. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.
Cory AH; Chen J; Cory JG
Anticancer Res; 2006; 26(2A):1289-95. PubMed ID: 16619536
[TBL] [Abstract][Full Text] [Related]
6. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
[TBL] [Abstract][Full Text] [Related]
7. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
[TBL] [Abstract][Full Text] [Related]
8. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells.
Magrini R; Russo D; Ottaggio L; Fronza G; Inga A; Menichini P
J Cell Biochem; 2008 Aug; 104(6):2363-73. PubMed ID: 18442053
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
10. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
[TBL] [Abstract][Full Text] [Related]
11. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia and hypoxia mimetic cooperate to counteract tumor cell resistance to glucose starvation preferentially in tumor cells with mutant p53.
Chavez-Perez VA; Strasberg-Rieber M; Rieber M
Biochem Biophys Res Commun; 2014 Jan; 443(1):120-5. PubMed ID: 24275138
[TBL] [Abstract][Full Text] [Related]
13. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
14. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
15. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P
Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886
[TBL] [Abstract][Full Text] [Related]
16. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
17. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
Wang T; Lee K; Rehman A; Daoud SS
Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
[TBL] [Abstract][Full Text] [Related]
18. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
[TBL] [Abstract][Full Text] [Related]
19. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.
Lee K; Wang T; Paszczynski AJ; Daoud SS
Biochem Biophys Res Commun; 2006 Oct; 349(3):1117-24. PubMed ID: 16970918
[TBL] [Abstract][Full Text] [Related]
20. Metabolic utilization of exogenous pyruvate by mutant p53 (R175H) human melanoma cells promotes survival under glucose depletion.
Chavez-Perez VA; Strasberg-Rieber M; Rieber M
Cancer Biol Ther; 2011 Oct; 12(7):647-56. PubMed ID: 21832879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
